Table 3.
Cytotoxicity of 1–7 against three human cancer cell lines.
| Compound | IC50 ± SD (µM) a | ||
|---|---|---|---|
| KB | Hep G2 | MCF7 | |
| 1 | 23.5 ± 1.1 | 19.8 ± 1.5 | 23.7 ± 2.0 |
| 2 | 62.1 ± 4.5 | 44.8 ± 4.0 | 73.7 ± 2.8 |
| 3 | 59.0 ± 2.5 | 80.0 ± 3.0 | >100 |
| 4 | 64.7 ± 3.0 | 68.0 ± 2.5 | 80.9 ± 7.4 |
| 5 | 32.0 ± 0.0 | 71.4 ± 3.9 | 80.0 ± 4.5 |
| 6 | >100 | >100 | >100 |
| 7 | >100 | >100 | >100 |
| Ellipticine b | 0.31 ± 0.05 | 0.33 ± 0.05 | 0.40 ± 0.05 |
a Results are expressed as the means ± SD of three replicates. b Ellipticine was used as the positive control. Human epidermoid carcinoma (KB), human hepatocellular carcinoma (Hep G2), and human breast adenocarcinoma (MCF-7).